• CAPS Medical

  Led · Series A · Jul 2020

  Caps Medical develops a highly selective, minimally invasive non-thermal plasma device to treat solid tumors. The platform attacks cancer cells without damaging surrounding healthy tissue and aims to trigger an immune response to target additional tumor-specific cells. The technology was developed in The Technion’s Plasma Lab in collaboration with Rambam Health Care Campus and was translated into a product by a team led by Ilan Uchitel at MEDX Xelerator. Founded in 2018 by MEDX Xelerator and based in Netanya, Israel, the company has been supported by MEDX Xelerator, with Boston Scientific and MEDX Ventures Group as major shareholders in the incubator. The $3.5M Series A will enable Caps Medical to perform its first clinical trial and further develop its solid tumor treatment portfolio. The company expects that study results will contribute toward achieving regulatory clearance in the U.S.; Harel Gadot will serve as Executive Chairman of Caps Medical’s board.

No current team members are available.